Neurochem, Inc. To Present At CIBC World Markets Sixteenth Annual Healthcare Conference

MONTREAL, Nov. 3 /PRNewswire-FirstCall/ - Neurochem Inc. announced today that on Monday, November 7, 2005, Dr. Francesco Bellini, Chairman, President and CEO, will present Neurochem’s overall strategy and progress to date at the CIBC World Markets Sixteenth Annual Healthcare Conference to be held at the Waldorf-Astoria Hotel, New York. The presentation will take place at 3:30 P.M. Eastern Time. Following Dr. Bellini’s remarks, the corporate presentation will be available on the Company’s website at http://www.neurochem.com/Investor.htm#Presentation.

An audio webcast of Neurochem’s presentation can also be accessed three hours after the conference at http://conferences.cibcwm.com/health05/ Source code: november. This webcast will be available for 90 days through to February 7, 2006.

About Neurochem

Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company’s pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs. 1,3-propanedisulfonate (1,3PDS; Fibrillex(TM)) is designated as an orphan drug, is a Fast Track product candidate and is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of Fibrillex(TM) for the treatment of AA Amyloidosis was concluded in April 2005. The Company is in the process of submitting a New Drug Application (NDA) for Fibrillex(TM) that the FDA has agreed to file and review. 3-amino-1- propanesulfonic acid (3APS; Alzhemed(TM)), for the treatment of Alzheimer’s disease, is currently in Phase III clinical trials in both North America and Europe, and 3APS (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 (877) 680-4500 or visit our Web Site at: www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem’s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward- looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.

For further information, please contact: Lise Hebert, Ph.D. Tel: 1-450-680-4570 Vice President, Corporate Communications lhebert@neurochem.com

NEUROCHEM INC.

CONTACT: Lise Hebert, Ph.D.Vice President, Corporate Communications, (450)680-4570, lhebert@neurochem.com

MORE ON THIS TOPIC